The information that is now available highlights the significant role that MXD3 plays in the proliferation and stemness of PRAD, indicating that it has the potential to be a promising target for patients with PRAD.[34,35] On the other hand, additional tests are required to shed light on the chemical mechanisms that drive the phenomenon. Here, MXD3 is linked to prostate adenocarcinoma.